Hana Pharm Co Ltd (293480) - Total Liabilities
Based on the latest financial reports, Hana Pharm Co Ltd (293480) has total liabilities worth ₩98.98 Billion KRW (≈ $67.08 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hana Pharm Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Hana Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Hana Pharm Co Ltd (293480) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Hana Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hana Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HusCompagniet AS
CO:HUSCO
|
Denmark | Dkr1.81 Billion |
|
Southern Acids (M) Bhd
KLSE:5134
|
Malaysia | RM123.71 Million |
|
Nava Nakorn Public Company Limited
BK:NNCL
|
Thailand | ฿1.11 Billion |
|
Advanced Analog Technology
TWO:3438
|
Taiwan | NT$373.70 Million |
|
Concorde International Group Ltd.
NASDAQ:YOOV
|
USA | $10.17 Million |
|
BCnC Co. Ltd.
KQ:146320
|
Korea | ₩101.44 Billion |
|
Kino Polska TV SA
WAR:KPL
|
Poland | zł114.56 Million |
|
MODISON LIMITED
NSE:MODISONLTD
|
India | Rs2.28 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Hana Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 293480 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hana Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hana Pharm Co Ltd (2016–2024)
The table below shows the annual total liabilities of Hana Pharm Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩72.83 Billion ≈ $49.36 Million |
+3.46% |
| 2023-12-31 | ₩70.40 Billion ≈ $47.71 Million |
-9.24% |
| 2022-12-31 | ₩77.57 Billion ≈ $52.57 Million |
+50.34% |
| 2021-12-31 | ₩51.60 Billion ≈ $34.97 Million |
+16.74% |
| 2020-12-31 | ₩44.20 Billion ≈ $29.95 Million |
+3.50% |
| 2019-12-31 | ₩42.70 Billion ≈ $28.94 Million |
+15.43% |
| 2018-12-31 | ₩36.99 Billion ≈ $25.07 Million |
-38.60% |
| 2017-12-31 | ₩60.25 Billion ≈ $40.83 Million |
+1.94% |
| 2016-12-31 | ₩59.11 Billion ≈ $40.06 Million |
-- |
About Hana Pharm Co Ltd
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and an… Read more